Isaac Nuamah
Family · Henderson, NCNPI 1093280117
Payments from drug & device makers
Across 175 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$312
- Lilly USA, LLC$132
- AstraZeneca$103
- Pfizer$102
- Takeda Pharmaceuticals U.S.A., Inc.$92
- plus $645 from 23 others
What the payments were for
- Food & beverage$2,617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 94 | $1,231 |
| Novo Nordisk | 20 | $312 |
| Lilly USA, LLC | 8 | $132 |
| AstraZeneca | 7 | $103 |
| Pfizer | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Boehringer Ingelheim | 4 | $62 |
| GSK | 4 | $61 |
| Exact Sciences | 3 | $48 |
| Grifols USA, LLC | 2 | $45 |
| Corcept Therapeutics | 2 | $44 |
| Neurocrine Biosciences, Inc. | 3 | $44 |
| Amgen | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $29 |
| Teleflex LLC | 1 | $27 |
| Insulet Corporation | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Organon | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Medtronic | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,617 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 22 | $25,630 |
| RybelsusSemaglutide | 13 | $22,108 |
| OzempicSemaglutide | 21 | $20,144 |
| JardianceEmpagliflozin | 17 | $19,250 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,795 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,771 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,194 |
| Atorvastatin Calcium | 115 | $778 |
| Amlodipine Besylate | 121 | $769 |
| Rosuvastatin Calcium | 40 | $761 |
| Diclofenac Sodium | 12 | $557 |
| Metformin Hcl | 97 | $517 |
| Omeprazole | 34 | $492 |
| Lisinopril | 73 | $462 |
| Levothyroxine Sodium | 43 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $312 | $42,25234 claims |
| AstraZenecaFarxiga | $103 | $25,63022 claims |
| Boehringer IngelheimJardiance | $62 | $19,25017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Henderson
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.